Company intelligence / Profile preview

Imunon, Inc.

Huntsville, Alabama, United Statesinvestor.celsion.com ↗

Ownership: Public · IMNN
Development stage: Phase 3

Overview

Developing DNA-based immunotherapies with lead program IMNN-001 for advanced ovarian cancer. As of September 2024, reported continued development with consistent net losses of $14.6 million for the first nine months of 2024.

Therapeutic areas: OncologyInfectious Diseases
Modalities: DNA-based immunotherapynucleic acid vaccines
Industry: Biotech

Drug pipeline

10 assets

doxorubicin liposomal

Approved

9 more assets in the full pipeline.

Request access →

Partnerships

Multiple research institutions mentioned but not specifically named

Financials

Market cap: $6.3M
Total revenue: $0
Enterprise value: $7.3M

Beyond the preview

Go deeper on Imunon, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imunon, Inc..

Explore the full profile